364 related articles for article (PubMed ID: 22575210)
1. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
2. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
3. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
Halim AB
Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
[TBL] [Abstract][Full Text] [Related]
4. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
5. The current and future state of companion diagnostics.
Agarwal A; Ressler D; Snyder G
Pharmgenomics Pers Med; 2015; 8():99-110. PubMed ID: 25897259
[TBL] [Abstract][Full Text] [Related]
6. The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.
Trusheim MR; Berndt ER
Drug Discov Today; 2015 Dec; 20(12):1439-50. PubMed ID: 26542060
[TBL] [Abstract][Full Text] [Related]
7. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
8. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
9. Molecular tools for companion diagnostics.
Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U
N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023
[TBL] [Abstract][Full Text] [Related]
10. The economic value of companion diagnostics and stratified medicines.
Blair ED; Stratton EK; Kaufmann M
Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
[No Abstract] [Full Text] [Related]
11. [Companion diagnostics: significances and issues in its clinical application].
Miyachi H
Rinsho Byori; 2011 Jun; 59(6):602-9. PubMed ID: 21815484
[TBL] [Abstract][Full Text] [Related]
12. [Companion diagnostics and reimbursement system].
Tazawa Y
Rinsho Byori; 2013 May; 61(5):435-42. PubMed ID: 23947184
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
14. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
15. The impact of genetic biomarkers on drug and companion diagnostic return on investment.
Keeling P
Drug Discov Today; 2011 Oct; 16(19-20):850-1. PubMed ID: 21906694
[No Abstract] [Full Text] [Related]
16. Challenges in the clinical implementation of precision medicine companion diagnostics.
Keeling P; Clark J; Finucane S
Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic challenges facing pharmacogenomics.
Cohen J; Wilson A; Manzolillo K
Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
[TBL] [Abstract][Full Text] [Related]
18. The current status and future potential of personalized diagnostics: Streamlining a customized process.
Richmond TD
Biotechnol Annu Rev; 2008; 14():411-22. PubMed ID: 18606372
[TBL] [Abstract][Full Text] [Related]
19. The Health Technology Assessment of companion diagnostics: experience of NICE.
Byron SK; Crabb N; George E; Marlow M; Newland A
Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
[TBL] [Abstract][Full Text] [Related]
20. The biggest challenges currently facing companion diagnostic advancement.
Halim AB
Expert Rev Mol Diagn; 2014 Jan; 14(1):27-35. PubMed ID: 24308333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]